[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)
Determine if a study site for this clinical trial is near you. Contact the study to apply.
Find a Study SiteCall center
Email address
Condition
Treatment type
Investigational product
Phase
Sponsor
ClinicalTrials.gov identifier
Study number
Get answers to your questions about clinical trials.
Insulin icodec is a new medicine which is under development for use in humans and is not yet available at the pharmacy. It is being developed for the treatment of diabetes, a condition that causes high blood sugar levels. Insulin icodec will be investigated in participants with type 2 diabetes. Participant will get one dose of insulin icodec, which will be administered in the afternoon or evening of the day of dosing. The study will last for about 8 weeks. Insulin icodec will be injected into a skin fold with a small needle (subcutaneous application) using a pen injector prefilled with a volume of 3 milliliter (mL) (a little less than a quarter of a teaspoonful). The amount of insulin icodec participant will receive depends on participant's body weight. Participant must not participate if participant meets certain conditions called exclusion criteria, such as an age of above 18 years when the informed consent is signed or has serious health conditions. Female participant cannot take part if she is pregnant, breast-feeding or planning to become pregnant during the study period.
You may be eligible to participate in the study if you meet the following criteria:
For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
Determine if a study site for this clinical trial is near you. Contact the study to apply.
Find a Study Site